Episode Details

Novo is ending the HERMES and ATHENA ziltivekimab trials after a monitoring committee judged them unlikely to succeed, leaving ARTEMIS as its remaining Phase 3 cardiovascular path. We examine ADARx's IPO filing, the Aptar-Aceso ACT-101 collaboration in cystic fibrosis, and STEP Young semaglutide results in children ages six to under twelve. SynAct's resomelagon reanalysis asks what another rheumatoid arthritis trial must prove after two primary-endpoint misses. This late Labor Day edition reflects information available through Monday and previews Roivant and Pulmovant's PHocus mosliciguat data in pulmonary hypertension associated with interstitial lung disease. Alex Mercer and Maya Patel host the Daily Roundup for September 7. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.